30 closest matches · ranked by relevance
Triple Negative Breast Cancer · Endometrial Cancer · Hormone Receptor Positive, HER2 Negative Breast Cancer
Primary: Cohort 1 - Progression-free Survival (PFS) — 1.9 Months
Cancer
Primary: Provider to Patient Communication Score — 1.0423; 1.0723 score on a scale
Ovarian Cancer
Primary: Efficacy Patient Level — 26.9 percentage of participants
Malignant Solid Tumour
Primary: Number of Participants With Any (Serious and Non-Serious) Adverse Event Measured to Assess Safety and Tolerability. — 12 participants
Cancer · Depression · Pain
Primary: Proportion of Participants Receiving at Least One Drug/Dose Selection or Modification Based on PGx Results — 9 Participants
Hematologic Malignancy
Primary: Overall Survival — 79; 49 Participants
Recurrent Neuroendocrine Tumor · Metastatic Neuroendocrine Tumor
Primary: Tumor Response According to RECIST Criteria — 0; 0; 0; 5 Participants
Gastrointestinal Cancer
Primary: Annualized Count of Acute Care Visits — 3; 3.8 unplanned acute care visits in one year — p=0.80
Pancreatic Adenocarcinoma · Ovarian Cancer · Biliary Carcinoma
Primary: Safety: Toxicity Symptoms Graded According to CTCAE v4.03. — 61; 139; 411; 7 Number of Events
Advanced Non-small Cell Lung Cancer (NSCLC)
Primary: Response Rate (Centrally Assessed) — 13.6; 19.6 percentage of participants
Breast Cancer · Head and Neck Squamous Cell Carcinoma · Colorectal Cancer
Primary: Measure Mean Fluorescence Intensity of Histologically Confirmed Tumor vs Normal Tissue in Patients Undergoing Routine Surgery [Tumor to Background Ratio (TBR)] — 1.098…
Primary Stage IV Hepatobiliary · Esophageal · Colorectal Cancer
Primary: Number of Participants Who Perceived Increased Goals of Care Discussions — 43; 34 Participants
Leukemia · Lymphoma, Non-Hodgkin
Primary: Tumor Apoptosis — 7 Participants
Advanced Solid Tumors · Recurrent Solid Tumors
Primary: PK Outcome: Cmax of ONO-4538 — 26.0; 64.3; 242.0 µg/mL
Biopsy Proven Non Small Cell Lung Cancer · Head and Neck Cancer · Gastrointestinal Cancer
Primary: Tumor Volume — 93.55 cm^3
Malignant Solid Tumor
Primary: Cmax at Single Dose — 24.4; 68.8; 192; 214 μg/mL
Cancer
Primary: Interviews — 20 Interviews
Breast Cancer · Colorectal Cancer · Head and Neck Cancer
Primary: Sensitivity of the G8 Questionnaire — 76.5 % of Participants with a positive G8
Lung Cancer
Primary: Thoroughness of Invasive Staging, Multidisciplinary (MD) vs Serial Care (SC) — 108; 168; 70; 180 Participants — p=0.0007
Ovarian Cancer
Primary: Twelve-month Progression-free Survival (PFS) Rate in Participants — 65.7 percentage of participants
Cancer
Primary: Number of Participants With Positive Viral Infection — 19; 197; 71; 34 Participants
Metastatic Gastric Cancer · Metastatic Breast Cancer · Metastatic Colorectal Cancer
Primary: Number of Participants With Treatment-emergent Adverse Events — 1; 0; 3; 3 Participants
Advanced Cancer
Primary: Urinary and Fecal Excretion of LY2603618 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered — 72.2; 11.0 percentage of total dose
High Grade Glioma · Ependymoma
Primary: Safety of the Optune NovoTTF-200A System When Used Alone in Pediatric Patients With Recurrent High-grade Gliomas. — 0 Participants
Breast Cancer
Primary: Missed Fractions
Venous Thormboembolism
Primary: Total Number of Venous Thromboembolic Events (VTE) in Standard Dose Enoxaparin Arm at 17 Days — 2 participants
Adult Solid Neoplasm · Lymphoma
Primary: Direct Communication About Age-related Concerns: Number of Discussions Related to the Geriatric Assessment That Occur in the Clinic Visit Between the Patient, Oncology…
Lung Neoplasms · Lung Cancer
Primary: Clinically Significant Events (CSE) — .530 proportion of participants
Squamous Cell Carcinoma of the Oral Cavity
Primary: Area Under the Curve (AUC) for Matrine in Saliva — 4007.9 ng x h/mL
Advanced Cancer
Primary: Recommended Phase 2 Dose: Maximum Tolerated Dose — 400 milligrams (mg)